-
31.发明公开
公开(公告)号：KR1020100067708A
公开(公告)日：2010-06-22
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to suppress osteoclast differentiation and to prevent and treat osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The Vitis vinifera seed extract has 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanine. A method for manufacturing the Vitis vinifera seed extract comprises: a step of adding mixture solvent of water and acetone to pulverized Vitis vinifera seed and extracting at room temperature; a step of removing acetone and suturing sodium chloride and filtering; a step of extracting the extract with acetate and concentrating; and a step of adding chloroform to the concentrate and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，以抑制破骨细胞分化和预防和治疗骨质疏松症。 构成：用于预防或治疗骨质疏松症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物的原花青素值（PCV）为80-130，儿茶素和（ - ）表儿茶素为30％以下，原花青素为95-105％。 葡萄种子提取物的制造方法包括：将水和丙酮的混合溶剂加入粉状葡萄种子并在室温下提取的步骤; 去除丙酮并缝合氯化钠并过滤的步骤; 用醋酸提取提取物浓缩的步骤; 以及向浓缩物中加入氯仿并过滤的步骤。
-
公开(公告)号：KR102121946B1
公开(公告)日：2020-06-12
申请号：KR1020190151287
申请日：2019-11-22
Applicant: 가톨릭대학교 산학협력단
IPC: A61K35/747 , A23L33/135
-
公开(公告)号：KR101917419B1
公开(公告)日：2018-11-09
申请号：KR1020160049877
申请日：2016-04-25
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 Crif1을유효성분으로포함하는자가면역질환의예방또는치료용약학적조성물에관한것이다. 본발명에따른 Crif1은류마티스관절염의증상및 발병율억제와파골세포분화억제효과를가지며, 쇼그렌증후군및 다발성경화증의증상을효과적으로예방및 치료할수 있어, 자가면역질환의새로운치료제로사용될수 있는효과가있다.
-
公开(公告)号：KR101426689B1
公开(公告)日：2014-08-08
申请号：KR1020110036053
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/497 , A61K31/495 , A61K31/4164 , A61P37/00
Abstract: 본 발명은 Nutlin-3a 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 유효성분인 Nutlin-3a 화합물은 p53 과발현을 통해 IL-17의 발현을 억제시킴으로써 관절염 동물 모델에서 관절염을 개선시키는 효과 있으므로, 이를 유효성분으로 포함하는 본 발명의 조성물은 면역질환 예방 또는 치료에서 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020130105545A
公开(公告)日：2013-09-25
申请号：KR1020130028183
申请日：2013-03-15
Applicant: 가톨릭대학교 산학협력단
Abstract: PURPOSE: An ROR alpha is provided to suppress the activation of Th17 cells and to regulate immune response, thereby effectively treating and preventing various allergic diseases or autoimmune diseases. CONSTITUTION: A method for reducing the activation of Th17 cells comprises the step of promoting the expression or activation of ROR alpha by transducing a recombinant expression vector containing ROR alpha genes into Th17 cells. ROR alpha gene has a sequence of sequence number 11 or 12. The recombinant expression vector contains a promoter or an enhancer which promotes the expression or activation of ROR alpha. A composition for preventing and treating Th17 cell activation-related diseases contains an agent for promoting the expression or activation of ROR alpha; or Th17 cells in which the agent is transduced, as an active ingredient.
Abstract translation: 目的：提供RORα以抑制Th17细胞的活化并调节免疫应答，从而有效治疗和预防各种过敏性疾病或自身免疫性疾病。 构成：减少Th17细胞活化的方法包括通过将含有RORα基因的重组表达载体转导入Th17细胞来促进RORα的表达或活化的步骤。 RORα基因具有序列号11或12的序列。重组表达载体含有促进RORα表达或活化的启动子或增强子。 用于预防和治疗Th17细胞活化相关疾病的组合物含有促进RORα的表达或活化的药剂; 或Th17细胞作为活性成分。
-
Patent Agency Ranking
公开(公告)号：KR1020120118978A
公开(公告)日：2012-10-30
申请号：KR1020110036667
申请日：2011-04-20
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/428 , A61K38/17 , A61P19/02 , A61P17/00
CPC classification number: A61K38/1758 , Y10S514/885 , Y10S530/868
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.
Abstract translation: 目的：提供用于预防或治疗包括P53在内的免疫疾病的组合物，以抑制引起免疫疾病的炎性细胞因子IL-17。 构成：用于预防或治疗免疫疾病的组合物包括P53作为活性成分。 P53具有通过炎性细胞因子的形成抑制来预防或治疗免疫疾病的活性。 炎性细胞因子是IL-17。 该组合物还包括用于促进p53表达或促进蛋白质活性的物质。 用于预防或治疗的组合物包括编码P53的多核苷酸。 加密p53蛋白质的多核苷酸以连接到表达相同的载体的重组载体类型提供。 表达P53蛋白的表达载体是非病毒载体或病毒载体。
-
公开(公告)号：KR1020120095063A
公开(公告)日：2012-08-28
申请号：KR1020110014466
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/1758 , A61K38/20 , C07K14/4713 , C07K14/4746
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including p53 induced by il-27 is provided to increase expression of p53 by getting stimulation of the IL-27 and to enhance arthritis in animal models according to the expression of p53. CONSTITUTION: A composition for preventing or treating immunization diseases includes p53. The p53 has amino acid sequence described in the sequence number 1(SEQ ID NO:1) or 2. The composition additionally includes the interleukin-27(IL-27). The interleukin-27(IL-27) multiplies the activities of the gene expression of p53 or the p53 protein. The composition for preventing or treating immunization diseases includes a promoter and a vector containing polynucleotide which codes the p53. The polynucleotide has the base sequence described in the sequence number 3 or 4.
Abstract translation: 目的：提供一种用于预防或治疗由il-27诱导的免疫疾病包括p53的组合物，以通过刺激IL-27并根据p53的表达增强动物模型中的关节炎来增加p53的表达。 构成：用于预防或治疗免疫疾病的组合物包括p53。 p53具有序列号1（SEQ ID NO：1）或2所述的氨基酸序列。该组合物另外包括白细胞介素-27（IL-27）。 白介素-27（IL-27）将p53或p53蛋白的基因表达的活性相乘。 用于预防或治疗免疫疾病的组合物包括编码p53的启动子和含有多核苷酸的载体。 多核苷酸具有序列号3或4中描述的碱基序列。
-
公开(公告)号：KR101099021B1
公开(公告)日：2011-12-28
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 골관절염(osteoarthritis)의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도의 씨 추출물, 골관절염-
公开(公告)号：KR101096574B1
公开(公告)日：2011-12-20
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 골다공증의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 골다공증-
40.发明公开유럽종 포도의 씨 추출물의 제조방법 및 이를 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 有权制备VITIS VINIFERA PIP萃取物和药物组合物的方法，用于预防或治疗包含其中的RHEUMATOID ARTHRITIS
公开(公告)号：KR1020110036031A
公开(公告)日：2011-04-06
申请号：KR1020110020720
申请日：2011-03-09
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to reduce acetone use and to prevent and treat rheumatic arthtritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatic arthritis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier thereof. The extract is obtained by pulverizing Vitis vinifera seeds, extracting the seeds with a mixture solvent of acetone and water, removing acetone and saturating sodium chloride, extracting liquid with ethyl acetate and concentrating, adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄种子提取物的药物组合物，以减少丙酮使用并预防和治疗风湿性关节炎。 构成：用于预防或治疗风湿性关节炎的药物组合物含有葡萄籽种子提取物及其药学上可接受的载体。 提取物通过粉化葡萄种子获得，用丙酮和水的混合溶剂萃取种子，除去丙酮和饱和氯化钠，用乙酸乙酯萃取液并浓缩，加入氯仿和过滤。
-
-
-
-
-
-
-
-
-
Search Results
51
records
(took 0.035 seconds)
